A
Alain B. Labrique
Researcher at Johns Hopkins University
Publications - 270
Citations - 9515
Alain B. Labrique is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 43, co-authored 229 publications receiving 6682 citations. Previous affiliations of Alain B. Labrique include Johns Hopkins University School of Medicine.
Papers
More filters
Journal ArticleDOI
mHealth innovations as health system strengthening tools: 12 common applications and a visual framework
TL;DR: This new framework lays out 12 common mHealth applications used as health systems strengthening innovations across the reproductive health continuum and describes how these applications can be applied in the context of a women's health care system.
Journal ArticleDOI
Guidelines for reporting of health interventions using mobile phones: mobile health (mHealth) evidence reporting and assessment (mERA) checklist
Smisha Agarwal,Smisha Agarwal,Amnesty E LeFevre,Jaime Lee,Kelly L'Engle,Kelly L'Engle,Garrett Mehl,Chaitali Sinha,Alain B. Labrique +8 more
TL;DR: This paper presents the resulting 16 item checklist and a detailed explanation and elaboration for each item, with illustrative reporting examples, and expects that the use of these guidelines will standardise thequality of mHealth evidence reporting, and indirectly improve the quality of m health evidence.
Journal ArticleDOI
Evidence on feasibility and effective use of mHealth strategies by frontline health workers in developing countries: systematic review
TL;DR: Given the large‐scale adoption and deployment of mobile phones by health services and frontline health workers (FHW), the evidence on the feasibility and effectiveness of mobile‐based services for healthcare delivery is reviewed and synthesised.
Journal ArticleDOI
Hepatitis E virus infection.
Nassim Kamar,Jacques Izopet,Nicole Pavio,Rakesh Aggarwal,Alain B. Labrique,Heiner Wedemeyer,Harry R. Dalton +6 more
TL;DR: HEV infections can be diagnosed by measuring anti-HEV antibodies, HEV RNA or viral capsid antigen in blood or stool and management of immunocompromised individuals involves lowering the dose of immunosuppressive drugs and/or treatment with the antiviral agent ribavirin.
Journal ArticleDOI
Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis.
Adam L. Booth,Angus B. Reed,Sonia Ponzo,Arrash Yassaee,Mert Aral,David Plans,Alain B. Labrique,Diwakar Mohan +7 more
TL;DR: In this paper, a systematic review was conducted using standardized methodology, searching two electronic databases (PubMed and SCOPUS) for relevant literature published between 1st January 2020 and 9th July 2020.